Connection

Co-Authors

This is a "connection" page, showing publications co-authored by JEFFREY J MOLLDREM and SIJIE LU.
Connection Strength

3.077
  1. Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia. Cytotherapy. 2021 09; 23(9):793-798.
    View in: PubMed
    Score: 0.786
  2. A GVHD kill switch helps immune reconstitution. Blood. 2014 Jun 19; 123(25):3849-50.
    View in: PubMed
    Score: 0.483
  3. Hu8F4-CAR T cells with mutated Fc spacer segment improve target-specificity and mediate anti-leukemia activity in vivo. Res Sq. 2024 Feb 19.
    View in: PubMed
    Score: 0.236
  4. Vaccines in leukemia. Adv Pharmacol. 2004; 51:255-70.
    View in: PubMed
    Score: 0.234
  5. The basis of T-cell-mediated immunity to chronic myelogenous leukemia. Oncogene. 2002 Dec 09; 21(56):8668-73.
    View in: PubMed
    Score: 0.217
  6. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2. Front Immunol. 2018; 9:3153.
    View in: PubMed
    Score: 0.166
  7. Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. Clin Cancer Res. 2018 07 15; 24(14):3386-3396.
    View in: PubMed
    Score: 0.157
  8. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol. 2012 Dec 01; 189(11):5476-84.
    View in: PubMed
    Score: 0.108
  9. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res. 2012 Jul 01; 72(13):3153-62.
    View in: PubMed
    Score: 0.104
  10. The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1. J Immunother. 2012 May; 35(4):309-20.
    View in: PubMed
    Score: 0.104
  11. Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. PLoS One. 2011; 6(8):e23217.
    View in: PubMed
    Score: 0.099
  12. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood. 2011 Apr 21; 117(16):4262-72.
    View in: PubMed
    Score: 0.096
  13. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy. 2010 Dec; 12(8):1056-62.
    View in: PubMed
    Score: 0.093
  14. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One. 2010 Jul 26; 5(7):e11770.
    View in: PubMed
    Score: 0.092
  15. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003 Mar; 111(5):639-47.
    View in: PubMed
    Score: 0.055
  16. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res. 2013 Jan 01; 19(1):247-57.
    View in: PubMed
    Score: 0.027
  17. LFA-1 affinity regulation is necessary for the activation and proliferation of naive T cells. J Biol Chem. 2009 May 08; 284(19):12645-53.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.